Condition: COPD (Chronic Obstructive Pulmonary Disease) · Sponsor: AstraZeneca
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Athens, Alabama, United States | Terminated |
| Research Site | Cullman, Alabama, United States | Recruiting |
| Research Site | Fairhope, Alabama, United States | Terminated |
| Research Site | Huntsville, Alabama, United States | Terminated |
| Research Site | Mobile, Alabama, United States | Recruiting |
| Research Site | Sheffield, Alabama, United States | Withdrawn |
| Research Site | Gilbert, Arizona, United States | Recruiting |
| Research Site | Glendale, Arizona, United States | Withdrawn |
| Research Site | Mesa, Arizona, United States | Recruiting |
| Research Site | Mesa, Arizona, United States | Recruiting |
| Research Site | Phoenix, Arizona, United States | Terminated |
| Research Site | Tempe, Arizona, United States | Suspended |
+ 909 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06283966